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Abstract :  27 
Canine lymphoma is a heterogeneous group of diseases and many previous studies have 28 
evaluated the response of a mixed population of lymphoma cases to one specific treatment 29 
protocol.  The aim of this retrospective study was to describe the outcome and prognostic 30 
factors in 42 cases of multicentric centroblastic diffuse large B-cell lymphoma treated with 31 
either a COP-type (35%) or CHOP (64%) induction chemotherapy.  The objective response 32 
rate to induction therapy was 94%; entire dogs had a greater rate of complete versus partial 33 
remissions than neutered dogs (P=0.017).  Median progression free survival for the first 34 
remission (PFS1) was 182 days; absence of anaemia at diagnosis (P=0.002) and pre-treatment 35 
neutrophil:lymphocyte ratio (NLR) below 9.44 (P=0.015) were independently predictive of 36 
longer PFS1.  Fifty-eight percent of dogs received rescue protocols with an objective response 37 
rate of 81%; 31% of dogs received further rescue protocols (up to a total of 5) and the median 38 
number of protocols administered was 2.  Median overall survival (OS) was 322 days, the 1-39 
year survival rate was 38% and the 2-year survival rate was 9%.  Lymphocyte:monocyte ratio 40 
(LMR) above 1.43 (P=0.031), NLR below 11.44 (P=0.009), the combination of induction 41 
and rescue therapy (P=0.030) and the total number of doxorubicin doses used (P=0.002) 42 
were independently predictive of longer OS.  Use of a COP-type protocol induction compared 43 
to CHOP did not undermine OS providing doxorubicin was used as rescue therapy.   44 
 45 
Keywords : COP, CHOP, neutrophil:lymphocyte ratio, lymphocyte:monocyte ratio, 46 
doxorubicin, complete remission, partial remission. 47 
 48 
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Abbreviations: 50 
CL = Canine lymphoma 51 
NHL = Non-Hodgkin lymphoma 52 
WHO = World Health Organization 53 
DLBCL = Diffuse large B cell lymphoma 54 
mDLBCL-CB = Multicentric, centroblastic diffuse large B cell lymphoma 55 
CR =Complete Remission, PR = Partial Remission, SD = Stable Disease, PD = Progressive 56 
Disease.   57 
PFS1= Progression-free survival of the first remission 58 
PFS2 = Progression-free survival of second remission 59 
PFS3 = Progression-free survival of third remission 60 
PFS4 = Progression-free survival of fourth remission 61 
OS= Overall survival 62 
AMC = Absolute monocyte concentration 63 
ALC = Absolute lymphocyte concentration 64 
ANC = Absolute neutrophil concentration 65 
NLR = Neutrophil:Lymphocyte ratio 66 
LMR = Lymphocyte:Monocyte ratio 67 
ROC = Receiver operating characteristic.   68 
AUC = Area under the curve. 69 
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Introduction 71 
 72 
Canine lymphoma (CL) is one of the most prevalent cancers in dogs and the most prevalent 73 
haematopoietic cancer.1   B-cell immunophenotype and multicentric distribution of disease 74 
are the most common presentations.2–4  CL is considered to be an analogue of the human, 75 
Non-Hodgkin’s lymphoma (NHL),5,6 and both the WHO and updated Kiel morphological 76 
classifications of NHL have been shown to apply to CL.7,8  Since the common morphological 77 
subtypes of CL involve diffuse effacement of lymph node architecture with a monotypic 78 
population of lymphocytes, cytological review of fine needle aspirate samples is considered a 79 
sensitive and specific means of diagnosis,7,9,10 and is the most commonly-used method of 80 
diagnosis.11  Furthermore, cytology has been shown to be a reliable means of applying both 81 
the updated Kiel system of morphological classification8,10,12,13 and the WHO classification.14–82 
16  The most prevalent cytomorphological subtype of CL (WHO classification) is diffuse large 83 
B-cell lymphoma (DLBCL), reported to represent 48% of cases in dogs,7 and DLBCL can be 84 
subdivided in accordance with the Kiel classification into the centroblastic subtype 85 
(representing approximately 77% of cases), and the immunoblastic subtype (representing 86 
approximately 23% of cases).7 87 
 88 
Traditionally, outcome for CL has been described in the light of treatment with different 89 
chemotherapy protocols.  When treated with COP-type protocols,  CL cases have been 90 
reported to have a median first remission duration of 3-6 months and a 19% one-year survival 91 
rate,17,18 whereas those treated with a CHOP protocol have been reported to have a first 92 
remission duration of 8.4-11 months and a one-year survival rate of 50%.19–22  Nevertheless, 93 
these studies have been based on populations of heterogeneous cytomorphological subtypes 94 
of CL, and recent studies have shown that heterogeneity in these populations may be a 95 
significant confounding factor where prognosis is concerned.  Ponce et.al. (2004) 96 
demonstrated significant differences in survival between small groups of dogs with different 97 
cytomorphological subtypes of CL (using the Kiel classification) and Valli et. al. (2013) later 98 
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repeated and expanded these observations using the WHO classification of histological 99 
samples.23  Thus, the response of dogs with specific cytomorphological subtypes of CL to one 100 
of the chemotherapy protocols consistently used in the literature is difficult to predict.  101 
 102 
Aside from treatment protocol and cytomorphological subtype, many consistent prognostic 103 
factors for CL have been reported, for example WHO clinical substage,19,24,25 104 
immunophenotype,26–30 histopathological grade,24,29,31 anatomical location of disease32–35 and 105 
presence of anaemia at diagnosis.29,36  Other factors such as WHO stage of disease have 106 
shown prognostic significance in some studies,17,37 but not others.38  Many other features 107 
associated with a dog’s presentation may also be of prognostic value, but have been less well-108 
evaluated.  In human medicine, the pre-treatment absolute monocyte concentration (AMC),39 109 
absolute lymphocyte concentration (ALC)40 and the neutrophil:lymphocyte ratio (NLR)41 110 
have been found to be highly predictive of prognosis in diffuse large B cell lymphoma.  Other 111 
parameters for example the pre-treatment absolute neutrophil concentration and 112 
lymphocyte:monocyte ratio (LMR) have found prognostic significance in other solid 113 
tumours.42,43 In veterinary medicine, AMC44 and LMR45 have been found to be of prognostic 114 
value in lymphoma, whereas the NLR has not been found to affect prognosis.46  Pre-treatment 115 
absolute neutrophil concentration (ANC) has been found to be prognostic in acute 116 
leukaemia,47and both AMC and ALC have been found to be prognostic in canine 117 
osteosarcoma.48  The diagnostic utility of NLR in differentiating soft tissue sarcomas from 118 
benign neoplasms,49 and identifying bone marrow involvement in canine mast cell disease has 119 
been suggested.50,51 120 
 121 
The aim of this study was to describe the clinical presentation, response to treatment, 122 
progression-free survival (PFS) and overall survival (OS) of a homogenous group of dogs 123 
with multicentric, centroblastic diffuse large B-cell lymphoma (mDLBCL-CB) treated with 124 
standardised induction and rescue chemotherapy protocols, and to identify prognostic factors 125 
associated with this cytomorphological type of CL.  Since heterogeneous groups of CL 126 
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contain cases with established negative prognostic factors (for example T cell 127 
immunophenotype, cutaneous and hepatosplenic presentations), the hypothesis was that a 128 
homogenous group of mDLBCL-CB cases will have a longer PFS and OS than a 129 
heterogeneous population of CL cases.   130 
 131 
 132 
  133 
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Materials & Methods: 134 
 135 
Study population: Clinical records of the Royal Veterinary College (RVC) between 2008 and 136 
2016, and North Downs Specialist Referrals (NDSR) between 2010 and 2013, were reviewed 137 
retrospectively for multicentric CL cases.  Cases were included if they fulfilled the following 138 
criteria: a cytological or histological diagnosis of lymphoma from a peripheral lymph node,4 139 
confirmed B-cell immunophenotype (on flow cytometry, immunohistochemistry or PARR 140 
testing), a categorical diagnosis of DLBCL-CB on histopathology or review of cytological 141 
findings by a Board-certified clinical pathologist, induction chemotherapy treatment with a 142 
COP-type or CHOP protocol, naïve to cytotoxic treatment at the time of mDLBCL-CB 143 
diagnosis and where follow-up data to the end of the first remission were available.  Cases 144 
where therapy was commenced with l-asparaginase or glucocorticoid therapy within 10 days 145 
of initiation of cytotoxic treatment were included.  Cases of lymphoma that primarily 146 
involved extranodal tissue (or the categorization was equivocal), or in which treatment or 147 
survival were compromised by a comorbidity (for example end-stage renal failure or 148 
advanced congestive heart failure), were excluded.  Follow-up information was collected 149 
from clinical records of the institutions concerned or obtained from the records of the 150 
referring practices. 151 
 152 
Data collected:  For each case the following data was recorded: age; breed; sex; neuter status; 153 
bodyweight; clinical examination findings and concurrent disease status at diagnosis; 154 
cytology or histology; immunophenotype; haematology; biochemistry and urinalysis results, 155 
and diagnostic imaging findings.  Haematology reports were interrogated and the following 156 
white blood cell ratios were calculated: neutrophil:monocyte ratio (NMR); 157 
neutrophil:lymphocyte ratio (NLR) and lymphocyte:monocyte ratio (LMR).  Cases that had 158 
concurrent disease which could potentially confound the interpretation of elevated leukocytes 159 
(for example evidence of non-cancer-related inflammation detected on physical examination) 160 
were excluded from the analysis of the leukocyte concentrations and ratios.  Induction 161 
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protocols and their associated responses, dates of relapse, details of all rescue protocols used 162 
with their associated responses and time of subsequent relapse and the date and reason for 163 
death or euthanasia were also recorded. 164 
 165 
All available cytological specimens were reviewed by a Board-certified clinical pathologist 166 
(BS), to assure that the cytological features were consistent with the diagnosis of DLBCL-CB 167 
according to the WHO classification scheme.14,16  Histopathological classification was also 168 
performed where possible by Board-certified anatomical pathologists at the reference 169 
laboratories concerned, using the WHO classification.  Cases considered not to be DLBCL-170 
CB upon review were excluded.  The methods used for immunophenotyping were recorded 171 
and immunophenotypic results obtained with flow cytometry were classified as normal or 172 
aberrant after Gelain et. al.52   173 
 174 
Haematology, serum biochemistry and urinalysis results at diagnosis were classified as 175 
normal or abnormal according to the reference intervals of the diagnostic laboratories 176 
concerned.  Haematology results from the chemotherapy treatments during the induction 177 
protocols were scrutinized and the incidence and severity of neutropenic episodes (as defined 178 
by VCOG CTCAE 1.1)53 were recorded; a composite “neutropenia score” was then formed by 179 
assigning points to each neutropenic event equivalent to the VCOG grade of neutropenia and 180 
adding up all points acquired throughout the induction protocol. 181 
 182 
Diagnostic imaging findings (computed tomography, radiography, ultrasonography or a 183 
combination thereof) at diagnosis were recorded.  Using this information the assigned stage 184 
and substage according to WHO criteria4 were reviewed.   Bone marrow aspirate or biopsy 185 
was not routinely performed and so cases were categorised as presumptive stage V by 186 
identification of circulating neoplastic cells in peripheral blood, on review of the blood smear 187 
by a board-certified clinical pathologist.   188 
 189 
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Details of induction and rescue chemotherapy protocols were recorded.  Induction protocols 190 
were classified as or CHOP (cyclophosphamide, vincristine, prednisolone and doxorubicin), 191 
Supplementary Table 1, or COP-type (an 8 week induction protocol involving 192 
cyclophosphamide, vincristine and prednisolone with or without one subcutaneous dose of 193 
cytarabine on the first day of treatment18), Supplementary Table 2.  The CHOP category was 194 
comprised of both 19- and 25-week Madison-Wisconsin protocols.  Cases needed a minimum 195 
of 28 days on a treatment protocol to be classed as either COP-type or CHOP; those who 196 
died, were euthanased, or whose treatment was changed less than 28 days after starting a 197 
treatment protocol, were classified as having progressive disease and excluded from statistical 198 
comparison of treatment protocols.  Dogs who achieved remission with COP-type protocols 199 
were subsequently treated with the LMP oral maintenance protocol (involving chlorambucil, 200 
methotrexate and prednisolone) until disease relapsed; dogs who received the CHOP 201 
protocols did not receive maintenance chemotherapy.  202 
 203 
Rescue protocols were categorised as DMAC (involving dexamethasone, melphalan, 204 
actinomycin-D and cytarabine), Supplementary Table 3, COP, doxorubicin-based or 205 
lomustine-based, Supplementary Table 4.  Categories describing a dog’s total combination 206 
of chemotherapy protocols were defined as: COP-type with no rescue, CHOP with no rescue, 207 
COP-type with doxorubicin-based rescue, CHOP with doxorubicin-based rescue, COP-type 208 
with non-doxorubicin-based rescue and CHOP with non-doxorubicin-based rescue.  The total 209 
number of protocols a dog received, and the number of doxorubicin doses each dog received 210 
through the entirety of its treatment were recorded.  Dogs that received 4 doses of 211 
doxorubicin throughout induction and rescue treatment (equivalent to one CHOP protocol) 212 
were compared with those that received 1-3 doses (less than a CHOP protocol) and those who 213 
received 5-8 doses (equivalent with induction and rescue with CHOP-based therapy).  214 
Chlorambucil was substituted for cyclophosphamide in dogs who developed sterile 215 
haemorrhagic cystitis.  Dogs received echocardiography to monitor their systolic function at 216 
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the start of doxorubicin therapy; this was repeated at the sixth dose of doxorubicin if the 217 
planned cumulative total dose of doxorubicin exceeded 6 doses (180mg/m2).   218 
 219 
Response to induction and rescue treatments were evaluated at each visit using VCOG 220 
criteria54 based on physical examination and additional tests at clinician discretion.  Cases 221 
were classed as complete remission (CR) if lymph nodes had returned to normal size; partial 222 
remission (PR) when lymph nodes remained enlarged but had reduced in size by at least 50% 223 
and no new lesions were recognized; progressive disease (PD) was used for occurrence of 224 
new lesions or increase in size of enlarged lymph nodes by at least 25%; and stable disease 225 
(SD) as a change in size of lymph nodes which was not sufficient to be classified as PD or PR 226 
with no occurrence of new lesions.  The objective response rate was defined as the sum of 227 
complete and partial remission rates.  A response to treatment must have been maintained for 228 
at least 28 days from the date it was first recorded to be classified as CR or PR.  Progression-229 
free survival (PFS) was defined as the time from the administration of the first lymphoma 230 
treatment (either cytotoxic drug, glucocorticoids or l-asparaginase), to disease relapse, 231 
progression or death from any cause; PFS1 was used to denote the PFS for the first remission, 232 
PFS2 for the second, and so forth.  Dogs that had treatment changed for reasons other than 233 
disease progression (for example due to patient’s demeanour) were censored from PFS 234 
analysis at the point the treatment was altered.  Overall survival (OS) was defined as the time 235 
between the administration of the first lymphoma treatment and death or euthanasia.54  Dogs 236 
that remained alive at the end of the follow-up period or who were lost to follow-up were 237 
censored from OS analysis.  238 
 239 
Statistical analysis:  Data were described and analysed using IBM SPSS Version 22 and 240 
Graphpad Prism™ (version 6).  Data were assessed for normality by visual plotting and use of 241 
the Shapiro-Wilk test.  Univariable analysis of response to treatment was performed using 242 
binary logistic regression; Log-rank and Cox proportional hazard regression were used to 243 
analyse the effect of multiple variables on PFS and OS.  Where analyses of different 244 
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treatment protocols were performed, the CHOP or doxorubicin-based groups were used as the 245 
comparator, given the acceptance of doxorubicin-based protocols as the standard of care for 246 
CL therapy.20  The alpha level was set at P=0.05 for significance.  ROC curve analysis was 247 
performed to assign cut-off values to continuous variables used for the prediction of a PFS or 248 
OS exceeding a certain time, usually its median value; a minimum area under the curve of 0.7 249 
was required for the ROC model to be considered.  Comparison of groups with different 250 
survival times was performed using Fisher’s exact test for categorical variables.  Student’s 251 
(two-tailed) t-test and Mann-Whitney U test for parametric and non-parametric continuous 252 
variables respectively.   253 
 254 
  255 
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Results 256 
 257 
Clinical Presentation 258 
Search results revealed 91 cases of canine B cell lymphoma; out of these, 65 cases of 259 
multicentric CL were identified and 45 dogs were classified as mDLBCL-CB by the same 260 
board-certified clinical pathologist; 35 dogs from the RVC and 10 from NDSR.  Thirty-one 261 
breeds were represented, and the most common were cross-breeds (8 dogs), Jack Russell 262 
terriers (4), golden retrievers (2), beagles (2), West Highland white terriers (2) and flat-coated 263 
retrievers (2).  The mean age was 8.1 years (standard deviation 2.63 years) and the median 264 
bodyweight was 28kg (range: 3.4-59.5kg).  Seventeen dogs (38%) were female (16 neutered, 265 
1 entire), and 28 (62%) were male (18 neutered, 10 entire).  Median follow-up period was 316 266 
days (range 6-1375 days); at the end of the study period, 36 dogs had died or been euthanized 267 
due to lymphoma, 4 had been euthanased for another reason, 4 dogs remained alive and 1 dog 268 
was lost to follow-up.  Reasons for euthanasia other than lymphoma were cellulitis (1 dog) 269 
and heart failure (3 dogs).  The dog that developed cellulitis was euthanased 6 days after 270 
starting treatment and the dogs that developed heart failure were euthanased 316 days, 790 271 
days and 1297 days after starting treatment.   272 
 273 
The key characteristics of the populations of dogs from the Royal Veterinary College and 274 
North Downs Specialist Referrals were not significantly different.  All dogs resided in the 275 
South-East of England, and most lived in urban areas.  All dogs were owned by fee-paying 276 
clients and none were referred to partake in clinical trials.  Both groups of dogs had 277 
approximately equal gender representation (RVC 70% male versus NDSR 60% male), 278 
bodyweight (RVC median bodyweight 28kg versus NDSR 27kg) and age (RVC median age 279 
8yo versus NDSR 9yo).  There was a similar distribution of disease stage, but a greater 280 
proportion of RVC dogs presented as substage a (62%, versus 40% for NDSR).  None of 281 
these differences were statistically significant (P>0.05).      282 
 283 
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Haematology findings from before the administration of anticancer treatment (including 284 
steroids or l-asparaginase) were available for 29 dogs.  Eleven dogs (38%) were anaemic 285 
(median PCV 33%, range 29-37%, all non-regenerative or insufficiently-regenerative), 7 dogs 286 
(24%) had a neutrophilia, 12 dogs (41%) were lymphopenic, one dog (3%) had monocytosis 287 
and one dog (3%) had a lymphocytosis.  Median absolute leukocyte concentrations and ratios 288 
are displayed in Table 1.  Pre-treatment serum biochemistry and urinalysis were available for 289 
35 dogs; 10 (29%) had biochemical abnormalities, the most common of which were 290 
hyperbilirubinaemia and increased activities of serum ALT and ALP in 4 dogs (11%) and 291 
elevated cholesterol in 3 dogs (9%).  All dogs with hyperbilirubinaemia were stage 4 or 5.  292 
Five of 35 dogs had abnormalities detected on urine dipstick; bilirubinuria was observed in 293 
the 4 dogs with hyperbilirubinaemia (11%) and proteinuria (defined as at least 2+ protein on 294 
dipstick analysis, in association with an unreactive urinary sediment, a urine specific gravity 295 
of less than 1.030, and the absence of haematuria) was seen in 3 dogs (9%). 296 
 297 
Immunophenotyping was performed by flow cytometry in 37 dogs (82%), by 298 
immunohistochemistry in 7 dogs (16%), and by PARR in 1 dog (2%).  Full flow cytometry 299 
results were available for 32 dogs; for 5 dogs, only the immunophenotype was available, 300 
details of the markers run and graphs were unavailable for scrutiny. A comprehensive set of 301 
markers (including CD3, CD5, CD21, CD34, CD45 and CD79a) was available for 23 dogs.  302 
Out of these, 12 dogs (52%) had a normal immunophenotype (consisting of positive labelling 303 
with CD21, CD79a and CD45) and 11 dogs (48%) had an aberrant immunophenotype; two 304 
dogs (18%) were classified as aberrant phenotypes due to the additional co-expression of T 305 
cell markers (CD3 in one dog and CD5 in the other), whereas the remaining 9 dogs (82%) had 306 
additional co-expression of CD34 or absent expression of CD21, CD79a, or CD45.  Two dogs 307 
had more than one aberration (Table 2).  The two dogs that expressed CD34 were classed as 308 
lymphoma cases rather than acute leukaemias because of the absence of both cytopaenias and 309 
circulating neoplastic cells. 310 
 311 
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Stage was documented for 35 dogs (78%).  Twenty-one dogs (60%) had thoracic and 312 
abdominal imaging, 13 with CT and 8 with thoracic radiographs and abdominal 313 
ultrasonography;  6 dogs (17%) had abdominal ultrasonography without thoracic imaging.  314 
Nineteen dogs (54%) had fine needle aspiration cytology of the liver and spleen. 315 
Eight dogs (23%) were categorised as stage 3, 18 (51%) as stage 4, and 9 (26%) as stage 5; 316 
(four with circulating neoplastic cells and 5 with extranodal tissue involvement).  Substage 317 
information was available for 44 dogs; 25 (57%) were substage a and 19 (43%) were substage 318 
b.   319 
 320 
Induction Treatment and Response  321 
Twenty-seven dogs (60%) were treated with CHOP induction, versus 15 (33%) COP-type; 3 322 
dogs (7%) had progressive disease or death below 28 days, making them ineligible for 323 
placement in COP-type or CHOP treatment groups.  Nine dogs (20%) were pre-treated with l-324 
asparaginase, 3 before a COP-type protocol and 6 before a CHOP protocol (median time 325 
before the protocol started was 1 day).  Three dogs (7%) were pre-treated with prednisolone 326 
(median time before protocol started 3 days).  Haematology nadirs after chemotherapy 327 
treatments in the induction protocols were available for 25 dogs; of these, 14 dogs (56%) 328 
developed at least one episode of neutropenia, and the median neutropenia score for these 329 
dogs was 3 (range 1-13).  A greater proportion of dogs from NDSR were induced with a 330 
CHOP protocol (80%) than RVC (60%), however this difference was not statistically 331 
significant (P=0.286). 332 
 333 
The objective response rate to induction treatment was 94%; 34 dogs (76%) obtained a CR, 8 334 
dogs (18%) obtained a PR, and three dogs (6%) developed PD.  Ninety percent of entire dogs 335 
had complete responses to treatment whereas 55% of neutered dogs had complete responses 336 
to treatment (P=0.017); no other variables were found to have a significant effect on response 337 
to induction therapy.  Thirty-seven dogs (82%) completed the induction protocol, 7 dogs 338 
(16%) had progressive disease during induction treatment, and one dog’s (2%) induction 339 
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protocol was changed while it had a partial response to treatment due to the dog’s aggressive 340 
behaviour. 341 
 342 
First Remission Progression-Free Survival  (PFS1) 343 
Median PFS for the first remission (PFS1) was 182 days (95% CI: 144-228 days).  There was 344 
no difference in PFS1 between the two institutions (P=0.710).  Dogs that were not anaemic at 345 
presentation had a significantly longer median PFS1 (254 days, 95% CI: 189-319 days) than 346 
those that were anaemic on presentation (median 147 days, 95% CI: 22-272 days; P=0.002, 347 
Fig.1).  Dogs with a neutrophil:lymphocyte ratio below a cut-off value of 9.44 had longer 348 
median PFS1 (216 days, 95% CI: 138-294 days) than those with NLR above 9.44 (median 349 
PFS1 104 days, 95% CI: 0-213 days; P=0.015).  The cut-off value of 9.44 had a 84% 350 
sensitivity and 64% specificity of predicting the probability of PFS1 exceeding its median 351 
value, 182 days (AUC 0.75).  Dogs with a neutropenia score above 1.5 during induction 352 
therapy had a significantly longer median PFS1 (254 days, 95% CI: 141-367 days), than dogs 353 
with a score below 1.5 that had a median PFS1 (216 days, 95% CI: 38-394 days; P=0.049).  354 
The cut-off value of 1.5 had a sensitivity of 50% and specificity of 86% for predicting the 355 
probability of PFS1 exceeding its median of 182 days (area under the curve 0.7).  Use of a 356 
COP-type protocol provided shorter median PFS1 (147 days, 95%CI: 73-221 days) than 357 
CHOP (median PFS1 251 days, 95% CI: 215-293 days; P=0.000, Fig.2) and achieving a 358 
complete response was associated with longer PFS1 (246 days, 95% CI: 183-309 days) than a 359 
partial response (median 105 days, range 32-178 days; P=0.003).  No other variables were 360 
found to have any significant effect on PFS1.   361 
 362 
On multivariable analysis, only the absence of anaemia at diagnosis (P=0.005) and treatment 363 
with a CHOP protocol over a COP-type protocol (P=0.008) were found to be independently 364 
predictive of a longer PFS1.  365 
 366 
Rescue Therapy and Subsequent Progression-Free Survival 367 
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Out of the 42 dogs (93%) that responded to induction treatment, 39 dogs (93%) relapsed, two 368 
dogs (5%) remained in remission at the time of study completion, and one dog (2%) was lost 369 
to follow-up.  The three dogs (7%) that had progressive disease with induction therapy did not 370 
receive rescue therapy, and were euthanased.  For the 37 dogs (82%) that completed the 371 
induction protocol, the median time between protocol completion and disease relapse was 118 372 
days (range 7-309 days); 120 days (range 7-309 days) for dogs treated with CHOP protocol, 373 
and 49.5 days (range 7-208) with COP-type (P=0.01).  Twenty-five dogs (55%) received 374 
rescue protocols, comprised of 14 (56%) doxorubicin-based, 6 (24%) COP-based protocols, 3 375 
(12%) DMAC and 2 (8%) lomustine-based.  Ten dogs (67%) that received COP-type 376 
induction had rescue treatments, versus 15 (55%) that received CHOP; the distribution of 377 
rescue treatments is illustrated in Table 3.  A greater proportion of dogs from RVC received 378 
rescue protocols (73% versus 40% from NDSR, P=0.024). 379 
 380 
The objective response rate to the first rescue protocol was 86%; 15 dogs (68%) achieved CR, 381 
4 dogs (18%) achieved PR, 3 dogs (14%) developed PD.  The median PFS2 was 147 days 382 
(95% CI: 104-190 days).  The only variable with a significant effect on PFS2 length was 383 
response to treatment; dogs who had a CR had a median PFS2 of 166 days (95% CI: 132-199 384 
days), dogs that had a PR had median PFS2 56 days (95% CI: 25-87 days) and those who 385 
didn’t respond to treatment had a median PFS2 of 14 days (range 1-14 days; P=0.000).   386 
 387 
Fifteen dogs received a second rescue protocol. Protocols used were: 6 (40%) lomustine-388 
based, 4 (27%) doxorubicin-based, 4 (27%) DMAC, and 1 (6%) COP.  The objective 389 
response rate was 28%; 2/14 dogs (14%) each obtained a CR, PR and SD, whereas 8 dogs 390 
(58%) developed PD.  Median PFS3 was 23 days (95% CI: 9-37 days).  Eleven dogs received 391 
a third rescue protocol; 5 (45.5%) were lomustine-based, 3 (27.5%) were DMAC, 2 (18%) 392 
received a clinical trial drug and 1 (9%) was doxorubicin-based.  The objective response was 393 
60%; 2/10 dogs (20%) obtained CR, 4 dogs (40%) a PR, while 2 dogs each maintained SD 394 
and developed PD.  Median PFS4 was 32 days (95% CI: 18-46 days).  Four dogs received a 395 
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fourth rescue protocol; one case received a clinical trial drug, one received DMAC, one 396 
masitinib and the other received alternating doses of bleomycin and mitoxantrone.  All 397 
maintained SD and the median PFS5 was 39 days (range 28-111 days).  Statistical analysis of 398 
factors influencing the duration of PFS3, PFS4 and PFS5 was not performed due to small 399 
group sizes. 400 
 401 
Overall, 5 dogs (12%) received a COP-type induction protocol with no rescue, and 12 dogs 402 
(29%) received a CHOP induction protocol with no rescue.  Eight dogs (19%) received a 403 
COP-type induction followed by rescue protocols which contained doxorubicin, 2 dogs (5%) 404 
received COP-type induction followed by rescue protocols which did not contain 405 
doxorubicin, 9 dogs (21%) received CHOP induction followed by rescue protocols which 406 
contained doxorubicin, and 6 dogs (14%) received a CHOP induction followed by rescue 407 
protocols which did not contain doxorubicin. 408 
 409 
The median number of treatment protocols received was 2 (1-5).  Thirty-seven dogs (82%) 410 
received doxorubicin at some point during their overall treatment.  The median number of 411 
doxorubicin doses for those dogs receiving this drug at some point in induction and rescue 412 
therapy was 4 (range 1-8; Table 4); the total number of doxorubicin doses did not differ 413 
significantly between dogs from RVC and NDSR (P=0.259).  The 3 dogs who were 414 
euthanased due to heart failure had a total number of 3, 4 and 5 doses of doxorubicin.  No 415 
cardiotoxicity was seen in the 8 dogs that received more than 5 doses of doxorubicin (total 416 
dose exceeding 150mg/m2). 417 
 418 
Overall Survival (OS) 419 
The median OS for all dogs was 322 days (95% CI: 259-385 days).  No significant difference 420 
in OS was found between the two institutions (P=0.366).  OS was significantly shorter for 421 
large dogs (P=0.010); using an ROC (AUC 0.73) a cut-off value of 31.15kg was found, with 422 
82% sensitivity and 70% specificity for predicting OS of less than the median of 322 days.  423 
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Dogs with a lower NLR (P=0.047) and a higher LMR (P=0.020) had a longer OS; using 424 
ROC analysis a LMR with a cut-off of 1.43 was found with a sensitivity of 83% and 425 
specificity of 63% for predicting OS greater than the median (AUC 0.72), Fig. 3, and a cut-426 
off for NLR of 11.44 predicted survival less than 90 days with 80% sensitivity and 100% 427 
specificity (AUC 0.87), Fig. 4.  428 
 429 
Dogs that attained CR with induction therapy had a significantly longer OS (median 400 days, 430 
95% CI: 291-509 days) than dogs that attained a PR (median OS 169 days, 95% CI: 57-281 431 
days; P=0.037).  Dogs that attained CR with the first rescue protocol had a significantly 432 
longer OS (median OS 493 days, 95% CI: 383-603 days) than those that developed PD or SD 433 
(median OS 216 days, 95% CI: 86-346 days; P=0.009), but there was no significant 434 
difference in OS between dogs that had a CR or a PR (median OS 422 days, range 214-630 435 
days; P=0.693).  Dogs that received CHOP induction had a median OS of 401 days (95% 436 
258-544 days) whereas dogs that had a COP-type induction had a median OS of 257 days 437 
(95% CI: 157-357 days); this difference was not significant (P=0.313) 438 
 439 
Dogs that received rescue protocols had a significantly longer OS (median 401 days, 95% CI: 440 
288-514 days) than dogs that received no further treatment when lymphoma recurred (median 441 
OS 227 days, 95% CI: 132-322 days; P=0.009).  However, the total number of treatment 442 
protocols a dog received had no significant effect on OS (P=0.351).  Dogs that received COP-443 
type induction and no rescue therapy had a median OS of 192 days (95% CI: 153-231 days) 444 
compared with 316 days (95% CI: 219-413 days) for dogs that received a CHOP protocol and 445 
no rescue (P=0.024).   No significant difference in OS was found between dogs that received 446 
a CHOP induction protocol with no rescue therapy, and those that received COP-type 447 
induction followed by doxorubicin-based rescue therapy (P=0.213).  No significant 448 
difference in OS was found between dogs that received a CHOP induction protocol with no 449 
rescue therapy and dogs that received a CHOP induction followed by non-doxorubicin-based 450 
rescue therapy (P=0.925); however, dogs that received CHOP induction followed by 451 
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doxorubicin-based rescue therapy had a significantly longer OS (median 706 days, 95% CI: 452 
350-1062 days) compared with CHOP induction alone (P=0.04; Fig. 5).  453 
 454 
Overall, the number of doxorubicin doses (from 0-8) was highly significantly associated with 455 
longer overall survival (P=0.000).  When dogs that were not given doxorubicin were 456 
excluded from analysis, the strong association remained (P=0.002, Table 5).  Dogs that 457 
received 1-3 doses of doxorubicin had a median OS of 216 days (95% CI: 24-408 days), 458 
which was not significantly different to dogs that had 4 doses, equivalent to a complete 459 
CHOP protocol (median OS 322 days, 95% CI: 280-364 days, P=0.777), but significantly 460 
shorter than dogs that had 5-8 doses (median OS 706 days, 95% CI: 297-1115 days, P=0.049, 461 
Fig. 6).  462 
 463 
The two dogs with expression of the T cell markers CD3 and CD5 had a subjectively shorter 464 
OS of 32 and 262 days compared with the rest of the study group (median OS 422 days, 95% 465 
CI: 260-584 days; P=0.031).  No such apparent difference in OS was noted with other 466 
aberrations in immunophenotype.     467 
 468 
On multivariable analysis, the variables found to be independently predictive of OS were 469 
NLR (P=0.009), LMR (P=0.031), and the combination of induction and rescue protocols 470 
(P=0.030) and the number of doxorubicin doses (for the dogs who received doxorubicin, 471 
P=0.002).  No other variables had a significant effect on OS. 472 
 473 
Prolonged and Short Survival Groups 474 
In this study, the 6-month survival rate was 73%, the 1-year survival 38% and the 2-year 475 
survival rate was 9%.   Dogs living more than 1 year had lower median bodyweight (mean 476 
22.5kg versus 31kg, P=0.019), were less likely to be anaemic on presentation (prevalence of 477 
anaemia at diagnosis of 11% versus 53%, P=0.049), had a CR with induction therapy (100% 478 
versus 64%, P=0.007) and when the dogs who received doxorubicin were considered, those 479 
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who received more doxorubicin doses were more likely to survive greater than one year 480 
(median number of 5 doxorubicin in dogs living greater than one year compared with 4 doses, 481 
for those that lived less than 1 year, P=0.031).  Statistical analysis of dogs living longer than 482 
2 years was not performed due to small group size. 483 
 484 
Dogs with shorter survivals than 6 months had lower rates of CR with induction therapy (42% 485 
versus 91%, P=0.001), were older (mean age of 9.5 years versus 7.6 years, P=0.031) and less 486 
likely to be treated with rescue therapy (27% receiving rescue versus 69%, P=0.031) than 487 
those who lived over 6 months. 488 
  489 
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Discussion 490 
 491 
In this study, a homogenous population of mDLBCL-CB cases are described.  The median 492 
PFS1 and OS of the whole group (182 days and 322 days respectively), and proportions 493 
surviving to 1 and 2 years (38% and 9% respectively) were lower than19,55,56 or similar to57,58 494 
previous reports of groups containing mixed subtypes of multicentric CL.  The OS of dogs in 495 
this study may not have been greater than that reported in mixed groups because many 496 
previous studies have been designed to evaluate a specific chemotherapy protocol, whereas 497 
this study evaluated a specific subtype of disease.  A homogeneous population also lacks the 498 
potential influence of subtypes of disease that have much longer survival times for example 499 
T-zone lymphoma,59 or shorter survival times for example lymphoblastic lymphomas.23  The 500 
level of treatment a dog received varied in this study, including dogs that were given 501 
treatments which are not considered the “standard of care,” prescribed for reasons such as 502 
finance or owner convenience.  When specific combinations of induction and rescue therapy 503 
are evaluated, greater OS times are seen, for example dogs who received CHOP induction 504 
followed by doxorubicin-based rescue had a median OS of 706 days (95% CI: 350-1062 505 
days).  506 
 507 
The response to induction treatment of mDLBCL-CB (objective response rate of 94%, 508 
complete response rate of 76%) was high.  This rate has been similar in some studies18,58,60 509 
and lower in others.19,55,56 Since mDLBCL-CB is the most prevalent type of lymphoma in 510 
dogs,7 a level of similarity between this study group and a random selection of CL cases 511 
would be expected.  Studies of mixed immunophenotype groups are likely to have included 512 
dogs with less responsive variants of the disease for example indolent lymphomas, that may 513 
not achieve complete responses.59  In this study group, entire dogs had a significantly higher 514 
rate of complete responses to induction therapy, however a greater proportion of entire dogs 515 
were treated with CHOP induction therapy than neutered dogs (73% versus 61%) and the low 516 
number of entire dogs (n=11) throws the independence of this finding into question.    517 
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 518 
The presence of anaemia at diagnosis was shown to be associated with a significantly shorter 519 
PFS1 and was significantly more common in the group of dogs who survived less than one 520 
year, compared with dogs that survived over 1 year.  The negative prognostic value of 521 
anaemia in canine lymphoma has been demonstrated in previous studies,36,61,62 although the 522 
aetiology is unclear.  Bone marrow infiltration by neoplastic lymphocytes has been 523 
hypothesized.  However, one study found no significant difference in occurrence of marrow 524 
infiltration between groups of anaemic and non-anaemic dogs with lymphoma, and no 525 
significant difference in haematocrit between dogs with marrow involvement and those 526 
without.62 Anaemia of inflammatory disease is another potential aetiology.  A previous study 527 
has shown no laboratory evidence of this in a group of dogs with lymphoma, although 528 
decreased response of the bone marrow to erythropoietin is still possible.63  The 529 
pathophysiological mechanism associating anaemia with a poor prognosis is unclear.  One 530 
theory suggests that the state of chronic hypoxia may induce expression of proteins which 531 
enable cancer cells to deal better with stress; increased concentration of one such protein, 532 
vascular endothelial growth factor has been associated with a poorer prognosis in canine 533 
lymphoma,64 and both anaemia and a poorer prognosis in humans with NHL.65 534 
 535 
Choice of a CHOP induction protocol over a COP-type protocol was shown as independently 536 
prognostic for PFS1 in this study, in line with previous publications.18  The superior PFS1 537 
associated with the CHOP protocol may be related to both the longer duration of treatment 538 
and the use of another agent, doxorubicin.  In agreement with other publications,66,67 this 539 
study found an association between the development of neutropenia and PFS1.  Since data on 540 
the development of neutropenia were only available for fewer than half of the dogs, and the 541 
prevalence of neutropenia among these dogs was low, we believe that assessment of the 542 
prognostic effect of neutropenia in this study was statistically under-powered.  The prevalence 543 
of neutropenia may have been low because dogs induced with a COP-type protocol would 544 
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have received a less immunosuppressive and shorter induction period compared to other 545 
studies, and because dose reductions were often performed following neutropenic episodes. 546 
 547 
Response to the first rescue protocol (86%) and the median PFS2 (147 days) were similar to 548 
the response to induction therapy (94%) and the median PFS1 (182 days).  Such findings have 549 
been described before.68 For a number of dogs in this study group, the first rescue protocol 550 
can be regarded as “re-induction” since the median time between completing induction 551 
therapy and relapse was 118 days, making the development of appreciable drug resistance 552 
less likely, and secondly a number of dogs who were induced with a COP-type protocol 553 
received a doxorubicin-based rescue therapy.  The response rates and remission durations 554 
associated with the second, third and fourth rescue protocols were more similar to previous 555 
reports of rescue treatment for lymphoma when drug-resistance is established.69–72   556 
 557 
This study has shown the independent prognostic significance of the pre-treatment 558 
neutrophil:lymphocyte ratio (NLR) in predicting progression-free survival and OS in canine 559 
mDLBCL-CB.  Absolute leukocyte counts and their ratios are ways of measuring different 560 
aspects of systemic inflammation and in cases of cancer systemic inflammation may be 561 
caused by tumour-related inflammation.43 Tumour-related inflammation is associated with 562 
cancer progression73 and in human medicine NLR has been recognised as holding prognostic 563 
significance in diffuse large B cell lymphoma,41 and many solid tumours.43  In veterinary 564 
medicine, NLR has been shown to be of some prognostic significance (on univariable but not 565 
multivariable analysis) in canine mast cell tumours.74  Mutz et.al recently reported no 566 
prognostic significance of NLR in a study of canine multicentric lymphoma treated with a 567 
CHOP protocol.46  If the findings of our study are supported by subsequent work, the apparent 568 
disagreement with the study of Mutz et.al may be due to an innate feature of mDLBCL-CB 569 
and the homogenous population of mDLBCL-CB cases in this study.  Conversely, increased 570 
NLR is a very non-specific finding and despite screening dogs for concurrent disease, it is 571 
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possible that the results are confounded by dogs with sub-clinical benign conditions, for 572 
example dental disease, otitis externa, or pancreatitis.   573 
 574 
We have reported that high NLR values (above a cut-off of 9.44 for PFS1 and 11.44 for OS), 575 
correspond to a poor prognosis.  In human medicine, a cut-off value of 3.5 is established, 576 
above which DLBCL patients have both a significantly poorer PFS and overall survival.41  577 
Such high NLR cut-off values may make this test insensitive in veterinary medicine; however 578 
it may also reflect that neutrophilia and lymphopenia due to stress is more common in canine 579 
patients than humans, and so significant NLR levels will need to be in excess of that expected 580 
from a normal stress leukogram.  Previous veterinary studies have evaluated absolute 581 
monocyte and lymphocyte counts in cancer; prognostic significance has been shown in canine 582 
osteosarcoma,48 and in some studies of canine lymphoma44 but not others.46  LMR has 583 
previously been reported as prognostic in human NHL,75 in canine mast cell disease74 and in 584 
canine lymphoma.76  This study concurs with the previous report of the prognostic 585 
significance of LMR for survival in mDLBCL-CB.  However just as for the significance of 586 
NLR, caution is needed in interpreting LMR values due to the non-specific aetiologies of its 587 
elevation.  588 
 589 
This study has demonstrated that use of a rescue protocol, particularly rescue therapy 590 
involving doxorubicin, and the total number of doxorubicin doses received to be a strong 591 
prognostic factor in mDLBCL-CB cases.  These observations should be interpreted with 592 
caution as many dogs who received a higher number of doses of doxorubicin are likely to be 593 
owned by the most committed owners, and subsequent doxorubicin treatments were unlikely 594 
to be offered unless the dog had responded to the drug previously. Thus, dogs who received 595 
the most doxorubicin may have been selected by lack of drug resistance relative to the other 596 
dogs.  This could highlight an innate tractability in a subset of dogs with mDLBCL-CB which 597 
has yet to be identified.  The lack of significantly different OS between dogs that received a 598 
COP-type induction followed by doxorubicin-based rescue therapy and dogs that received a 599 
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CHOP induction protocol (with or without non-doxorubicin-based rescue therapy) suggest 600 
that the temporal placement of doxorubicin in either a dog’s induction or rescue treatment 601 
does not seem to be of prognostic value.  Being able to give a COP-type protocol for 602 
induction therapy without the concern of undermining prognosis may offer flexibility in 603 
choice of induction protocols to veterinarians and their clients.  604 
 605 
Aberrant immunophenotypes of CL have been described based on flow cytometry,52,77 606 
although their prognostic significance is largely uncertain.  Possession of an aberrant 607 
immunophenotype overall held no prognostic value in this study, however statistical analysis 608 
of the particular aberrations present was not possible due to small group sizes.  The poorer OS 609 
experienced by the two cases that expressed T cell markers is interesting; further work is 610 
necessary to investigate different prognoses conferred by different aberrations of 611 
immunophenotype.    612 
 613 
In this study group, the majority of dogs presented in clinical stage 4 or 5, and almost half of 614 
them in substage b.  These proportions may be normal for mDLBCL-CB, or the apparent bias 615 
towards more advanced disease may be a result of thorough application of staging tests and 616 
the phenomenon of stage migration38 or selection bias since all cases were recruited at 617 
specialist referral centres.  Stage, substage, gender, and bodyweight have been previously 618 
reported as prognostic in canine lymphoma17,19,36,37,61,67 and a previous publication has 619 
reported a different behaviour of stage 5 cases with extranodal involvement compared with 620 
those with haematological involvement.55  None of these findings were supported by this 621 
study.  Prognostic significance of clinical stage in previous, heterogeneous groups of 622 
lymphoma cases may have been confounded by the inherent variability of different CL 623 
subtypes.  Equally, the prevalence of certain factors was too low in the current study for 624 
meaningful inclusion in statistical analysis. 625 
 626 
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Different factors were found to have prognostic significance for PFS1 and OS.  Although the 627 
application of some variables to PFS1 would be meaningless, the discrepancy between the 628 
prognostic significance of LMR, response to induction therapy and the presence of anaemia at 629 
diagnosis for PFS1 versus OS is harder to explain.  These findings may have arisen due to the 630 
population size and the effect of censoring some cases from OS analysis which were included 631 
in PFS1 analysis.  Nevertheless if these findings hold true in larger populations one 632 
explanation could be that features such as some absolute cell concentration or ratios reflect 633 
the susceptibility of the disease to treatment at that point in time, thus they may be prognostic 634 
for length of the subsequent remission only, rather than for OS. 635 
 636 
In this study, the authors feel justified in combining two different hospital populations since 637 
they are not significantly different in any key feature of clinical presentation or induction 638 
therapy, and their cytology has been reviewed by the same board-certified clinical 639 
pathologist.  The only significant difference between the two groups is that a higher 640 
proportion of cases from RVC received a rescue protocol; we feel that this doesn’t make the 641 
combination of populations any less valid since the choice of whether to use rescue therapy or 642 
not is dependent on the owners’ wishes and finances, and it is not possible for these variables 643 
to be well controlled in retrospective studies.  The finding of this study with regard to rescue 644 
therapy was that a response to rescue therapy is positively prognostic, and this is corroborated 645 
by other studies.68   646 
 647 
This study was limited by its retrospective nature and relatively small population size; 648 
resultantly the study is most likely underpowered and significant findings may have been 649 
missed.  A large number of variables have also been statistically evaluated, giving the 650 
possibility that false positive associations have arisen by chance.  Larger multi-institution 651 
studies are clearly needed to clarify this study’s findings.  The recruitment of cases from 652 
speciality referral centres might have also biased the caseload to those which had more 653 
complicated presentations, more likely to be of substage b, and with more committed owners. 654 
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Although the study describes the response to different treatments, the authors caution that a 655 
retrospective study represents weak evidence to guide future therapeutic decisions.  We hope 656 
that this study provides grounds for prospective controlled trials in this area.  Investigation of 657 
the genetic differences within this group of dogs may help to predict the dogs that will 658 
develop drug resistance sooner versus those will demonstrate prolonged response to therapy.78   659 
 660 
In conclusion, this study has shown the behaviour of disease and response to certain drugs in 661 
a population of dogs with mDLBCL-CB.  Absence of anaemia at diagnosis and a pre-662 
treatment NLR below 9.44 were associated with longer PFS1 while LMR above 1.43, and 663 
NLR below 11.44 were associated with longer OS.  The use of rescue therapy and the number 664 
of doxorubicin doses received were strongly associated with longer OS.  The choice of 665 
induction protocol did not influence survival, providing doxorubicin was later used as rescue 666 
therapy.  Further, prospective studies are warranted to further assess the importance of these 667 
findings.  668 
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 Legends to Tables & Figures 910 
 911 
Table 1:  Pre-treatment absolute leukocyte concentrations and ratios from the study 912 
population (n=25).  *The two ratios which were found to have a significant effect on outcome 913 
have been marked in bold; NLR was independently predictive for PFS1 in (P=0.025), and OS 914 
(P=0.009).  LMR was independently predictive of OS (P=0.031). 915 
 916 
Table 2:  Signalment and cellular markers of dogs with aberrant immunophenotypes.  The 917 
aberrant markers for each dog are placed in bold.  “+” = present, “-“ = absent.  FN = female 918 
neutered, ME = male entire, MN= male neutered.  Statistical analysis of individual 919 
aberrations was not performed due to small sample sizes. 920 
 921 
Table 3:  Rescue protocols used after COP-type and CHOP induction protocols (n=42).  922 
*Bleomycin / mitoxantrone. 923 
#Masitinib. 924 
 925 
Table 4 : Distribution of the total number of dogs receiving different numbers of doxorubicin 926 
doses and the placement of doxorubicin therapy through induction and rescue treatment. 927 
 928 
Table 5 : Significant differences between the total number of doxorubicin doses received and 929 
OS.  Median OS values are given for each dose.  Significant p values are marked in bold.  930 
Hazard Ratios (HR) are given for categories where significant differences in OS were found.   931 
*Only one dog received 7 doses of doxorubicin hence the OS value is actual rather than 932 
median. 933 
 934 
Figure 1: Kaplan Meier curves for the first progression free survival times (PFS1) of dogs 935 
with mDLBCL-CB (n=28); presence of anaemia at diagnosis was independently predictive of 936 
the length of first remission on cox hazard regression.  Dogs who were anaemic at diagnosis 937 
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(dotted line) had a median PFS1 of 147 days (95% CI: 22-272 days) and an increased hazard 938 
of remission ending (hazard ratio 5.6) compared with those that were not anaemic on 939 
presentation that had a median PFS of 254 days (95% CI: 189-319 days), P=0.002. 940 
 941 
Figure 2: Kaplan Meier curves for the first progression free survival times (PFS1) of dogs 942 
with mDLBCL-CB (n=42); induction protocol was independently predictive of the length of 943 
first remission on cox hazard regression.  Dogs who were treated with the CHOP protocol 944 
(solid line) had a median PFS1 of 251 days (95% CI: 215-293 days) and decreased hazard of 945 
remission ending (hazard ratio 0.22) compared with a median PFS1 of 147 days (95%CI: 73-946 
221 days) for those that were treated with the COP-type protocol (P=0.000). 947 
 948 
Figure 3: Kaplan Meier curves for the overall survival times (OS) of dogs with mDLBCL-949 
CB (n=28); pre-treatment lymphocyte:monocyte Ratio (LMR) was independently predictive 950 
of OS length on cox hazard regression (P=0.031).  Dogs who had a LMR above a cut-off of 951 
1.43 had a median OS of 353 days (95% CI: 208-498 days), while those who had an LMR 952 
below 1.43 had a median OS of 174 days (94-254), P=0.01; hazard ratio 0.315.   953 
 954 
Figure 4: Kaplan Meier curves for the overall survival times (OS) of dogs with mDLBCL-955 
CB (n=28); pre-treatment Neutrophil : Lymphocyte Ratio (NLR) was independently 956 
predictive of OS length on cox hazard regression (P=0.009).  Dogs who had a NLR above a 957 
cut-off of 11.44 had a median OS of 128 days (0-325), while those who had an NLR below 958 
11.44 had a median OS of 322 days (95% CI: 241-403 days); P=0.000, hazard ratio 7.7.   959 
 960 
Figure 5: Kaplan Meier curves for the overall survival times (OS) of dogs with mDLBCL-961 
CB (n=28); combination of total treatment was independently predictive of OS length on Cox 962 
hazard regression (P=0.030).  In comparison with dogs that received CHOP induction 963 
followed by no rescue therapy, dogs who received a COP-type protocol with no rescue had an 964 
increased hazard ratio for death of 4.2 (P=0.024), whereas dogs who received CHOP 965 
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induction followed by doxorubicin-based rescue therapy had a reduced hazard ratio for death 966 
of 0.330 (P=0.04).  No significant differences were seen between dogs that received COP-967 
type induction followed by doxorubicin-based rescue, dogs that received CHOP induction 968 
with no rescue protocol and dogs that received CHOP induction followed by a non-969 
doxorubicin-based rescue protocol. The two dogs that received COP-type rescue after COP-970 
type induction have been admitted from this graph for clarity.  971 
 972 
Figure 6: Kaplan Meier curves for the overall survival times (OS) of dogs with mDLBCL-973 
CB (n=37); the number of doses of doxorubicin received throughout induction and all rescue 974 
therapy was independently predictive of OS on cox hazard regression (P=0.002).  Compared 975 
with 1-3 doses of doxorubicin, dogs who received 5-8 doses had a decreased hazard ratio of 976 
death of 0.399 (P=0.049).  There was no statistically significant difference between dogs that 977 
received 4 doses and dogs that received 1-3 doses.   978 
 979 
Supplementary Table 1: The CHOP protocol.  The Madison Wisconsin 19-week CHOP 980 
protocol consisted of 4 repetitions of the above cycle of cytotoxic drugs; a tapering course of 981 
prednisolone is given in the first cycle, with discontinuation of the drug at the start by the start 982 
of the second cycle.  The Madison Wisconsin 25-week CHOP protocol involved a two-week 983 
break between cytotoxic drug treatments in the third and fourth cycles.  No maintenance 984 
chemotherapy was given with this protocol.  *mg/kg dosing was used for doxorubicin below a 985 
bodyweight of 10kg.   986 
 987 
Supplementary Table 2: The COP-type protocol.  Prednisolone was given throughout 988 
induction and maintenance phases of the protocol.  *A single dose of cytarabine was given 989 
subcutaneously on the first day of the treatment in some dogs.   990 
 991 
Supplementary Table 3: The DMAC Protocol.  This protocol consists of ongoing 2-week 992 
cycles as described in the table.  993 
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Supplementary Table 4: The single-agent protocols.  994 
 995 
